SIRT1 and neurodegenerative disease: The clinical success of sirtuin activating compounds (STACs) in neurodegenerative diseases relies overwhelmingly on developing new strategies and designing molecules based on the sirtuin chemistry and molecular pathways activated by SIRT1.